加减八珍汤联合放化疗对中晚期宫颈癌患者疗效及对生存期影响

Effect on Recent Effect and Survival Period of Modified Bazhen Decoction Combined with Radiotherapy and Chemotherapy in Treatment Middle and Advanced Cervical Cancer Patients

目的:观察加减八珍汤联合放化疗对中晚期宫颈癌患者的近期疗效及对其生存期的影响。方法:选取于2009年9月—2013年2月我院收治的中晚期宫颈癌患者100例,按照随机数表法将患者随机均分为观察组(n=50)和对照组(n=50),在常规放化疗的基础上,观察组患者加服加减八珍汤。比较两组患者的近期疗效、不良反应及生存期。结果:观察组患者的治疗总有效率为84.00%,其中完全缓解(CR)率为34.00%,部分缓解(PR)率为50.00%。对照组为58.00%,其中完全缓解(CR)率为16.00%,部分缓解(PR)率为42.00%。观察组的总有效率显著高于对照组(P<0.05)。观察组恶心呕吐及WBC减少的发生率分别为22.00%、44.00%,对照组为54.00%、54.00%,两组患者的恶心呕吐及WBC减少的发生率间存在显著差异(P<0.05)。观察组和对照组患者的口腔炎症、脱发、血小板下降等不良反应的发生率之间的差异无统计学意义(P>0.05)。观察组患者的1年生存率为92.00%,2年生存率为56.00%,3年生存率为30.00%,对照组为74.00%、34.00%、12.00%,两组之间的差异具有统计学意义(P<0.05)。结论:加减八珍汤可以有效改善放化疗的中晚期宫颈癌患者的预后,提高近期疗效,减少治疗的毒副作用,有效延长患者的生存期。

Objective ： To observe the recent efficacy and the influence on survival stage of the Modified Bazhen Decoction combined with radiotherapy and chemotherapy in patients with middle and advanced cervical cancer. Methods： 100 patients with middle and advanced cervical cancer in our hospital from September 2009 to February 2013 were selected. The patients were randomly divided into observation group （ n=50 ） and control group （ n=50 ） equally according to the random number table method. On the basis of conventional radiotherapy and chemotherapy, the patients in the observation group were treatment with the Modified Bazhen Decoction. Comparing the recent efficacy, adverse reaction and survival time of the two groups. Results ： The total effective rate of the observation group was 84.00%, with the CR rate 34.00%, and the PR rate 50.00%. The control group was 58.00%, with the CR rate 16.00%, and the PR rate 42.00%. The total effective rate of the observation group was significantly higher than that of the control group （ P〈0.05 ）. The incidence of nausea and vomiting and WBC reduction in the observation group were 22.00% and 44.00%. And the control group were 54.00% and 54.00%. There was a significant difference between the two groups in the incidence of nausea and vomiting and WBC reduction （ P〈0.05 ）. There was no significant difference in the incidence of oral inflammation, hair loss, thromboeytopenia and other adverse reactions between the observation group and the control group （P〉0.05）. In the observation group, the 1 year survival rate was 92.00%, 2 year survival rate was 56.00%, and the 3 year survival rate was 30.00%. In the control group were 74.00%, 34.00% and 12.00%. The difference between the two groups was statistically significant （ P〈0.05 ）. Conclusion ： Modified Bazhen Decoction can effectively improve the prognosis of the advanced cervical cancer patients in radiotherapy and chemotherapy, improve the recent efficacy, reduce the incidence of adverse reactions, prolong the survival time of the patients.